John G. Flannery

This paper introduces PERCEPT, a CRISPR delivery platform that enables multi-organ genome editing in vivo by chemically modifying CRISPR enzymes for targeted and efficient delivery.

This study shows that AAV-delivered truncated CFH gene therapy can reverse C3G in mice and suggests its potential for treating AMD.

This paper demonstrates a chemical-optogenetic approach that restores high-sensitivity motion vision in an IRD mouse model using a multi-branched photoswitch.

This paper demonstrates that AAV gene therapy targeting ON-bipolar cells in a canine model of LRIT3-CSNB significantly improves night vision and restores LRIT3 function.

This study shows that progranulin gene therapy in a CLN11 mouse model is time-sensitive, with early administration reducing retinal thinning but no benefit at later ages.

This study uses directed evolution to create AAV vectors with enhanced gene delivery to the outer retina in primates.